An international view of hydroxyethyl starches

Hydroxyethyl starch (HES) is one of the most frequently used plasma substitutes. A variety of different HES solutions exist worldwide, which differ greatly in their pharmacological properties. HES is classified according to its manufactured or in vitro molecular weight (MW) into high MW (450-480 kDa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Intensive care medicine 1999-03, Vol.25 (3), p.258-268
Hauptverfasser: TREIB, J, BARON, J.-F, GRAUER, M. T, STRAUSS, R. G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 268
container_issue 3
container_start_page 258
container_title Intensive care medicine
container_volume 25
creator TREIB, J
BARON, J.-F
GRAUER, M. T
STRAUSS, R. G
description Hydroxyethyl starch (HES) is one of the most frequently used plasma substitutes. A variety of different HES solutions exist worldwide, which differ greatly in their pharmacological properties. HES is classified according to its manufactured or in vitro molecular weight (MW) into high MW (450-480 kDa), medium MW (200 kDa), and low MW (70 kDa) starch preparations. However, this is not sufficient, because as HES is metabolized in vivo, its MW changes, and it is the in vivo MW which is responsible for the therapeutic and adverse effects of each HES. The rate of metabolization depends mainly on the degree of hydroxyethyl substitution (ranging from 0.4 to 0.7), and the C2/C6 ratio of hydroxyethylation. A high degree of substitution and a high C2/C6 ratio lead to a slow metabolization of HES, resulting in a large in vivo MW. Slowly degradable high MW HES 450/0.7 and medium MW HES 200/0.62 have a high in vivo MW and are eliminated slowly via the kidneys. As a result, these starches have a relatively long-lasting volume effect. When infusing higher volumes (>1500 ml) are infused, large molecules accumulate in the plasma. This can result in bleeding complications due to decreased factor VIII/von Willebrand factor, platelet function defects, incorporation into fibrin clots, and an unfavorable effect on rheological parameters. Rapidly degradable medium MW HES 200/0.5 or low MW HES 70/0.5 are quickly split in vivo into smaller, more favorable molecule sizes, resulting in faster renal elimination, shorter volume effect, and fewer adverse effects on coagulation and rheological parameters. For historical and marketing reasons, only slowly degradable, high MW HES (480/0.7) is available in the United States. In Europe, a large variety of HES solutions are available, dominated by medium MW, easily degradable HES (200/0.5). Because of increasing international competition and the availability of newly developed starches, it is important to be aware of the pharmacological properties of HES and the advantages and disadvantages of the individual preparations.
doi_str_mv 10.1007/s001340050833
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69734748</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2629187501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c345t-81eec1b63acd7526bc9e89951b4ad44b66a699249a97849d4a95cf8b11e741c13</originalsourceid><addsrcrecordid>eNpd0EtLw0AUBeBBFFurS7cSRNylzp25mcdSii8ouNF1mEwmNCVN6kyi5t870oKP1d18nMM9hJwDnQOl8iZQChwpzaji_IBMATlLgXF1SKaUI0tRIJuQkxDWUUqRwTGZAGVMQ6anZH7bJnXbO9-avu5a0yTvtftIuipZjaXvPkfXr8YmCb3xduXCKTmqTBPc2f7OyOv93cviMV0-Pzwtbpep5Zj1qQLnLBSCG1vKjInCaqe0zqBAUyIWQhihNUNttFSoSzQ6s5UqAJxEsMBn5HqXu_Xd2-BCn2_qYF3TmNZ1Q8iFlhwlqggv_8F1N8RnmpDHAiWBCRZRukPWdyF4V-VbX2-MH3Og-feK-Z8Vo7_Yhw7FxpW_9G62CK72wARrmsqb1tbhx0lQwJB_Ad-ed1M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>992871262</pqid></control><display><type>article</type><title>An international view of hydroxyethyl starches</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>TREIB, J ; BARON, J.-F ; GRAUER, M. T ; STRAUSS, R. G</creator><creatorcontrib>TREIB, J ; BARON, J.-F ; GRAUER, M. T ; STRAUSS, R. G</creatorcontrib><description>Hydroxyethyl starch (HES) is one of the most frequently used plasma substitutes. A variety of different HES solutions exist worldwide, which differ greatly in their pharmacological properties. HES is classified according to its manufactured or in vitro molecular weight (MW) into high MW (450-480 kDa), medium MW (200 kDa), and low MW (70 kDa) starch preparations. However, this is not sufficient, because as HES is metabolized in vivo, its MW changes, and it is the in vivo MW which is responsible for the therapeutic and adverse effects of each HES. The rate of metabolization depends mainly on the degree of hydroxyethyl substitution (ranging from 0.4 to 0.7), and the C2/C6 ratio of hydroxyethylation. A high degree of substitution and a high C2/C6 ratio lead to a slow metabolization of HES, resulting in a large in vivo MW. Slowly degradable high MW HES 450/0.7 and medium MW HES 200/0.62 have a high in vivo MW and are eliminated slowly via the kidneys. As a result, these starches have a relatively long-lasting volume effect. When infusing higher volumes (&gt;1500 ml) are infused, large molecules accumulate in the plasma. This can result in bleeding complications due to decreased factor VIII/von Willebrand factor, platelet function defects, incorporation into fibrin clots, and an unfavorable effect on rheological parameters. Rapidly degradable medium MW HES 200/0.5 or low MW HES 70/0.5 are quickly split in vivo into smaller, more favorable molecule sizes, resulting in faster renal elimination, shorter volume effect, and fewer adverse effects on coagulation and rheological parameters. For historical and marketing reasons, only slowly degradable, high MW HES (480/0.7) is available in the United States. In Europe, a large variety of HES solutions are available, dominated by medium MW, easily degradable HES (200/0.5). Because of increasing international competition and the availability of newly developed starches, it is important to be aware of the pharmacological properties of HES and the advantages and disadvantages of the individual preparations.</description><identifier>ISSN: 0342-4642</identifier><identifier>EISSN: 1432-1238</identifier><identifier>DOI: 10.1007/s001340050833</identifier><identifier>PMID: 10229159</identifier><identifier>CODEN: ICMED9</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Blood Coagulation - drug effects ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; Europe ; Glucose ; Hemorheology - drug effects ; Humans ; Hydroxyethyl Starch Derivatives - adverse effects ; Hydroxyethyl Starch Derivatives - pharmacokinetics ; Hydroxyethyl Starch Derivatives - pharmacology ; Intensive care ; Medical sciences ; Molecular Weight ; Pharmacokinetics ; Plasma ; Plasma Substitutes - adverse effects ; Plasma Substitutes - pharmacokinetics ; Plasma Substitutes - pharmacology ; Rheology ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; United States</subject><ispartof>Intensive care medicine, 1999-03, Vol.25 (3), p.258-268</ispartof><rights>1999 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c345t-81eec1b63acd7526bc9e89951b4ad44b66a699249a97849d4a95cf8b11e741c13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1718124$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10229159$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>TREIB, J</creatorcontrib><creatorcontrib>BARON, J.-F</creatorcontrib><creatorcontrib>GRAUER, M. T</creatorcontrib><creatorcontrib>STRAUSS, R. G</creatorcontrib><title>An international view of hydroxyethyl starches</title><title>Intensive care medicine</title><addtitle>Intensive Care Med</addtitle><description>Hydroxyethyl starch (HES) is one of the most frequently used plasma substitutes. A variety of different HES solutions exist worldwide, which differ greatly in their pharmacological properties. HES is classified according to its manufactured or in vitro molecular weight (MW) into high MW (450-480 kDa), medium MW (200 kDa), and low MW (70 kDa) starch preparations. However, this is not sufficient, because as HES is metabolized in vivo, its MW changes, and it is the in vivo MW which is responsible for the therapeutic and adverse effects of each HES. The rate of metabolization depends mainly on the degree of hydroxyethyl substitution (ranging from 0.4 to 0.7), and the C2/C6 ratio of hydroxyethylation. A high degree of substitution and a high C2/C6 ratio lead to a slow metabolization of HES, resulting in a large in vivo MW. Slowly degradable high MW HES 450/0.7 and medium MW HES 200/0.62 have a high in vivo MW and are eliminated slowly via the kidneys. As a result, these starches have a relatively long-lasting volume effect. When infusing higher volumes (&gt;1500 ml) are infused, large molecules accumulate in the plasma. This can result in bleeding complications due to decreased factor VIII/von Willebrand factor, platelet function defects, incorporation into fibrin clots, and an unfavorable effect on rheological parameters. Rapidly degradable medium MW HES 200/0.5 or low MW HES 70/0.5 are quickly split in vivo into smaller, more favorable molecule sizes, resulting in faster renal elimination, shorter volume effect, and fewer adverse effects on coagulation and rheological parameters. For historical and marketing reasons, only slowly degradable, high MW HES (480/0.7) is available in the United States. In Europe, a large variety of HES solutions are available, dominated by medium MW, easily degradable HES (200/0.5). Because of increasing international competition and the availability of newly developed starches, it is important to be aware of the pharmacological properties of HES and the advantages and disadvantages of the individual preparations.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Blood Coagulation - drug effects</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>Europe</subject><subject>Glucose</subject><subject>Hemorheology - drug effects</subject><subject>Humans</subject><subject>Hydroxyethyl Starch Derivatives - adverse effects</subject><subject>Hydroxyethyl Starch Derivatives - pharmacokinetics</subject><subject>Hydroxyethyl Starch Derivatives - pharmacology</subject><subject>Intensive care</subject><subject>Medical sciences</subject><subject>Molecular Weight</subject><subject>Pharmacokinetics</subject><subject>Plasma</subject><subject>Plasma Substitutes - adverse effects</subject><subject>Plasma Substitutes - pharmacokinetics</subject><subject>Plasma Substitutes - pharmacology</subject><subject>Rheology</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>United States</subject><issn>0342-4642</issn><issn>1432-1238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpd0EtLw0AUBeBBFFurS7cSRNylzp25mcdSii8ouNF1mEwmNCVN6kyi5t870oKP1d18nMM9hJwDnQOl8iZQChwpzaji_IBMATlLgXF1SKaUI0tRIJuQkxDWUUqRwTGZAGVMQ6anZH7bJnXbO9-avu5a0yTvtftIuipZjaXvPkfXr8YmCb3xduXCKTmqTBPc2f7OyOv93cviMV0-Pzwtbpep5Zj1qQLnLBSCG1vKjInCaqe0zqBAUyIWQhihNUNttFSoSzQ6s5UqAJxEsMBn5HqXu_Xd2-BCn2_qYF3TmNZ1Q8iFlhwlqggv_8F1N8RnmpDHAiWBCRZRukPWdyF4V-VbX2-MH3Og-feK-Z8Vo7_Yhw7FxpW_9G62CK72wARrmsqb1tbhx0lQwJB_Ad-ed1M</recordid><startdate>19990301</startdate><enddate>19990301</enddate><creator>TREIB, J</creator><creator>BARON, J.-F</creator><creator>GRAUER, M. T</creator><creator>STRAUSS, R. G</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>19990301</creationdate><title>An international view of hydroxyethyl starches</title><author>TREIB, J ; BARON, J.-F ; GRAUER, M. T ; STRAUSS, R. G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c345t-81eec1b63acd7526bc9e89951b4ad44b66a699249a97849d4a95cf8b11e741c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Blood Coagulation - drug effects</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>Europe</topic><topic>Glucose</topic><topic>Hemorheology - drug effects</topic><topic>Humans</topic><topic>Hydroxyethyl Starch Derivatives - adverse effects</topic><topic>Hydroxyethyl Starch Derivatives - pharmacokinetics</topic><topic>Hydroxyethyl Starch Derivatives - pharmacology</topic><topic>Intensive care</topic><topic>Medical sciences</topic><topic>Molecular Weight</topic><topic>Pharmacokinetics</topic><topic>Plasma</topic><topic>Plasma Substitutes - adverse effects</topic><topic>Plasma Substitutes - pharmacokinetics</topic><topic>Plasma Substitutes - pharmacology</topic><topic>Rheology</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>TREIB, J</creatorcontrib><creatorcontrib>BARON, J.-F</creatorcontrib><creatorcontrib>GRAUER, M. T</creatorcontrib><creatorcontrib>STRAUSS, R. G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Intensive care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>TREIB, J</au><au>BARON, J.-F</au><au>GRAUER, M. T</au><au>STRAUSS, R. G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An international view of hydroxyethyl starches</atitle><jtitle>Intensive care medicine</jtitle><addtitle>Intensive Care Med</addtitle><date>1999-03-01</date><risdate>1999</risdate><volume>25</volume><issue>3</issue><spage>258</spage><epage>268</epage><pages>258-268</pages><issn>0342-4642</issn><eissn>1432-1238</eissn><coden>ICMED9</coden><abstract>Hydroxyethyl starch (HES) is one of the most frequently used plasma substitutes. A variety of different HES solutions exist worldwide, which differ greatly in their pharmacological properties. HES is classified according to its manufactured or in vitro molecular weight (MW) into high MW (450-480 kDa), medium MW (200 kDa), and low MW (70 kDa) starch preparations. However, this is not sufficient, because as HES is metabolized in vivo, its MW changes, and it is the in vivo MW which is responsible for the therapeutic and adverse effects of each HES. The rate of metabolization depends mainly on the degree of hydroxyethyl substitution (ranging from 0.4 to 0.7), and the C2/C6 ratio of hydroxyethylation. A high degree of substitution and a high C2/C6 ratio lead to a slow metabolization of HES, resulting in a large in vivo MW. Slowly degradable high MW HES 450/0.7 and medium MW HES 200/0.62 have a high in vivo MW and are eliminated slowly via the kidneys. As a result, these starches have a relatively long-lasting volume effect. When infusing higher volumes (&gt;1500 ml) are infused, large molecules accumulate in the plasma. This can result in bleeding complications due to decreased factor VIII/von Willebrand factor, platelet function defects, incorporation into fibrin clots, and an unfavorable effect on rheological parameters. Rapidly degradable medium MW HES 200/0.5 or low MW HES 70/0.5 are quickly split in vivo into smaller, more favorable molecule sizes, resulting in faster renal elimination, shorter volume effect, and fewer adverse effects on coagulation and rheological parameters. For historical and marketing reasons, only slowly degradable, high MW HES (480/0.7) is available in the United States. In Europe, a large variety of HES solutions are available, dominated by medium MW, easily degradable HES (200/0.5). Because of increasing international competition and the availability of newly developed starches, it is important to be aware of the pharmacological properties of HES and the advantages and disadvantages of the individual preparations.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>10229159</pmid><doi>10.1007/s001340050833</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0342-4642
ispartof Intensive care medicine, 1999-03, Vol.25 (3), p.258-268
issn 0342-4642
1432-1238
language eng
recordid cdi_proquest_miscellaneous_69734748
source MEDLINE; SpringerLink Journals
subjects Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Blood Coagulation - drug effects
Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis
Europe
Glucose
Hemorheology - drug effects
Humans
Hydroxyethyl Starch Derivatives - adverse effects
Hydroxyethyl Starch Derivatives - pharmacokinetics
Hydroxyethyl Starch Derivatives - pharmacology
Intensive care
Medical sciences
Molecular Weight
Pharmacokinetics
Plasma
Plasma Substitutes - adverse effects
Plasma Substitutes - pharmacokinetics
Plasma Substitutes - pharmacology
Rheology
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
United States
title An international view of hydroxyethyl starches
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T06%3A15%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20international%20view%20of%20hydroxyethyl%20starches&rft.jtitle=Intensive%20care%20medicine&rft.au=TREIB,%20J&rft.date=1999-03-01&rft.volume=25&rft.issue=3&rft.spage=258&rft.epage=268&rft.pages=258-268&rft.issn=0342-4642&rft.eissn=1432-1238&rft.coden=ICMED9&rft_id=info:doi/10.1007/s001340050833&rft_dat=%3Cproquest_cross%3E2629187501%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=992871262&rft_id=info:pmid/10229159&rfr_iscdi=true